BioSpace News Archive

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will be participating at the following May investor conferences.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced its financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Palisade Bio, Inc. is announcing that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock for gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company.

ASLAN Pharmaceuticals will host a virtual KOL event, during which Company management will present new data from the interim analysis of the Phase 2 TREK-DX study of eblasakimab in dupilumab-experienced atopic dermatitis patients.

Elevation Oncology, Inc. announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.

Verastem Oncology announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024 at 3:35 pm EDT.

Ligand Pharmaceuticals Incorporated and Agenus Inc. announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program.

Catheter Precision, Inc. a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product, releases Q1 Financials, Operational Report for the quarter ending March 31, 2024.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced the Company has closed a Series B-1 Preferred Stock offering led by one of the Company’s long-time institutional investors, with gross proceeds of $11.6 million, bringing the total Series B / B-1 gross proceeds to $29.8 million.

Agenus Inc., a leader in discovering and developing novel immunological agents to treat various cancers, announced results for the first quarter 2024.